New HIV prevention pill tested after High-Risk exposure
NCT ID NCT04233372
Summary
This study tested a 3-drug combination pill called Delstrigo as an emergency prevention treatment for people who may have been recently exposed to HIV. 399 adults who went to the emergency room after possible HIV exposure took the pill daily for 28 days. Researchers tracked how many people completed the full treatment, monitored side effects, and checked if anyone still got HIV during follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department and HIV & HCV Clinical Research Unit University Hospital Nantes
Nantes, France
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
Conditions
Explore the condition pages connected to this study.